Holen Sie sich die Stockscreener-App
2.46
6.49%
0.15
Schlusskurs vom Vortag:
$2.31
Offen:
$2.3
24-Stunden-Volumen:
233.71K
Relative Volume:
0.44
Marktkapitalisierung:
$27.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.12M
KGV:
-1.567
EPS:
-1.5699
Netto-Cashflow:
$-15.68M
1W Leistung:
-1.20%
1M Leistung:
+10.31%
6M Leistung:
-39.71%
1J Leistung:
-32.04%
1-Tages-Spanne:
$2.22
$2.61
1-Wochen-Bereich:
$2.21
$2.82
52-Wochen-Spanne:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.46 | 27.69M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - ChartMill
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - ACCESS Newswire
Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - marketscreener.com
Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.aiA Platform to Conquer Rare Cancers - Palestineherald.com
Lantern Pharma to Debut Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut - marketscreener.com
Lantern Pharma Inc. Debuts Public Demonstration of withZeta.ai Platform - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lake Street Maintains Lantern Pharma(LTRN.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Lantern Pharma schedules FDA meeting on lung cancer trial changes By Investing.com - Investing.com Australia
Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial - TipRanks
Lantern Pharma (LTRN) Plans FDA Meeting for Trial Protocol Adjus - GuruFocus
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity - BioSpace
Lantern Pharma (LTRN) Plans FDA Meeting for Trial Protocol Adjustments - GuruFocus
Lantern Pharma schedules FDA meeting on lung cancer trial changes - Investing.com
Lantern Pharma IncSchedules Type C FDA Meeting For Harmonic Protocol Amendments - TradingView
Lantern Pharma (LTRN) Stock: Technical Chart (Risk Aversion) 2026-04-18Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Is Lantern Pharma (LTRN) stock gaining momentum (Weakens) 2026-04-18Stock Trading Network - Cổng thông tin điện tử tỉnh Tây Ninh
Funds report 834,752 Lantern Pharma (LTRN) shares in ownership update - Stock Titan
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET - ADVFN
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights - ADVFN
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - ADVFN
Lantern Pharma (LTRN) Stock Revenue Growth (Trend Strengthens) 2026-04-15High Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Lantern Pharma (LTRN) Launches AI Platform for Cancer Research - GuruFocus
Lantern Pharma launches AI platform for rare cancer research By Investing.com - Investing.com Australia
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Can - PharmiWeb.com
Lantern Pharma launches AI platform for rare cancer research - Investing.com
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development - marketscreener.com
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers - TipRanks
Lantern Pharma showcases withZeta.ai platform, outlines commercial architecture and near-term revenue strategy - TradingView
Lantern Pharma (NASDAQ: LTRN) showcases withZeta.ai rare cancer AI - Stock Titan
Is Lantern Pharma (LTRN) Stock Worth Buying Now | Price at $1.61, Down 0.68%Community Chart Signals - Xã Thanh Hà
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo Finance
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
LTRN PE Ratio & Valuation, Is LTRN Overvalued - Intellectia AI
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma Reports 2025 Financial Results - National Today
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - Issuewire
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Announces Termination of Proposed Public Offering - Issuewire
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):